Abstract
The ability of Y-24180, 4-(2-chlorophenyl)-2-[2-(4-isobutylphenyl)ethyl]- 6,9-dimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a] [1,4]diazepine to inhibit platelet-activating factor (PAF)-induced reactions was investigated. Y-24180 (0.0003-0.003 mg/kg, i.v.) dose-dependently inhibited PAF-induced bronchoconstriction in guinea pigs, but even at a high dose of 10 mg/kg, i.v., it was either inactive or weakly active against the bronchoconstriction induced by histamine, serotonin, acetylcholine, arachidonic acid, bradykinin, or leukotriene D4. Oral doses (0.003-0.1 mg/kg) of Y-24180 also prevented hemoconcentration due to PAF in a dose dependent manner and produced a parallel shift of the PAF dose-response curve. Y-24180 (0.0003-0.1 mg/kg, i.v.) and WEB 2086 (0.03-1 mg/kg, i.v.) dose-dependently reversed PAF-induced hypotension in anesthetized rats. In mice, PAF-induced lethality was inhibited by Y-24180 and WEB 2086 with ED50 values of 0.022 and 1.42 mg/kg, p.o., and 0.023 and 0.12 mg/kg, i.v., respectively. This protective effect of Y-24180 given p.o. persisted for at least 6 hr. In actively sensitized mice lethal anaphylactic shock was prevented by oral doses of Y-24180 and WEB 2086 with ED50 values of 0.095 and 0.69 mg/kg, respect...Continue Reading
References
Aug 1, 1987·Japanese Journal of Pharmacology·H MikashimaY Maruyama
Aug 7, 1986·European Journal of Pharmacology·S DesquandB B Vargaftig
Aug 1, 1987·Agents and Actions·R P CarlsonJ Chang
Mar 1, 1988·Prostaglandins·A K MyersP Ramwell
Apr 1, 1987·Immunopharmacology·J Casals-Stenzel
Aug 21, 1987·European Journal of Pharmacology·M PretolaniB B Vargaftig
May 1, 1987·Chemical & Pharmaceutical Bulletin·T TaharaY Maruyama
Aug 1, 1987·Japanese Journal of Pharmacology·M TerasawaY Maruyama
Jun 1, 1986·Immunopharmacology·D A HandleyR N Saunders
Feb 1, 1985·Nursing·M R Cohen
Feb 1, 1985·The Journal of Allergy and Clinical Immunology·A L Sheffer
Feb 26, 1985·European Journal of Pharmacology·Z TerashitaS Sumida
Oct 1, 1985·Prostaglandins·J M YoungJ S Clark
Jan 1, 1970·International Archives of Allergy and Applied Immunology·B B Levine, N M Vaz
Dec 1, 1972·The Journal of Experimental Medicine·J BenvenisteC G Cochrane
Dec 1, 1984·Immunopharmacology·D A HandleyR N Saunders
Dec 21, 1984·Science·E KorneckiR H Lenox
Apr 25, 1983·Life Sciences·Z TerashitaK Nishikawa
Sep 1, 1983·Prostaglandins·J BonnetP Bessin
Jun 1, 1983·British Journal of Pharmacology·A MyersP Ramwell
Jul 25, 1980·European Journal of Pharmacology·B B VargaftigJ Benveniste
Jan 1, 1981·Annals of the New York Academy of Sciences·B B VargaftigF Wal
Apr 1, 1982·Immunopharmacology·M Sánchez-CrespoJ Egido
Aug 27, 1982·European Journal of Pharmacology·B B VargaftigM C Medeiros
Citations
Mar 1, 1992·Agents and Actions·H OkamotoM Terasawa
Aug 1, 1993·International Journal of Immunopharmacology·H KomatsuT Okumoto
Jan 1, 1995·Journal of Lipid Mediators and Cell Signalling·M SaitoT Matsuda
Apr 15, 1996·Environmental Toxicology and Pharmacology·H KomatsuT Okumoto
Dec 9, 2003·Life Sciences·Yu-Ying Chao, Chung-Ren Jan
Jul 30, 2002·European Journal of Pharmacology·Naoki InagakiHiroichi Nagai
Apr 14, 1999·Life Sciences·S YamaguchiH Komatsu
Sep 30, 1999·Life Sciences·H KomatsuK Sugahara
Dec 1, 1999·Life Sciences·M MizukiT Tsuda
Feb 19, 2000·Prostaglandins & Other Lipid Mediators·M FujimuraT Matsuda
Jun 1, 1997·Journal of Lipid Mediators and Cell Signalling·H Le SolleuJ P Dubost
Dec 17, 2009·The Journal of Biological Chemistry·Nobuaki HirotaMotonao Nakamura
Jan 1, 1991·British Journal of Pharmacology·M WatanabeK Ohuchi
Jan 1, 1994·British Journal of Pharmacology·M WatanabeK Ohuchi
Dec 14, 1992·FEBS Letters·M NakamuraT Shimizu
Jul 6, 2000·Cytokine·H KusuharaM Terasawa
Jan 22, 2005·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Chung-Ren Jan, Yu-Ying Chao
May 26, 2004·Cellular Signalling·Chung-Ren Jan, Yu-Ying Chao
Mar 1, 2002·Journal of Autoimmunity·Yasuo TanakaYouji Mitsui
Jul 21, 1998·International Journal of Immunopharmacology·H Komatsu, M Amano